Rybelsus is a prescription tablet used to manage type 2 diabetes in adults. It belongs to a class of medications called GLP-1 receptor agonists, which were originally available only as injections. Approved by the FDA, Rybelsus is the first oral medication in this class, making it a pill-based alternative for people who prefer not to use needles.
FDA-Approved Uses
Rybelsus is approved as an add-on to diet and exercise to improve blood sugar control in adults with type 2 diabetes. It is not approved for type 1 diabetes.
In 2024, the FDA expanded the label to include a second indication: reducing the risk of major adverse cardiovascular events (heart attack, stroke, or cardiovascular death) in adults with type 2 diabetes. This makes Rybelsus the first and only oral GLP-1 medication with a cardiovascular risk reduction indication. In the large SOUL trial, the 14 mg dose reduced the combined risk of these events by 14% compared to placebo. Nonfatal heart attacks specifically were 26% less likely in patients taking the medication.
How Rybelsus Works
Rybelsus contains semaglutide, which mimics a natural gut hormone your body releases after eating. This hormone signals your pancreas to produce more insulin when blood sugar is high, while also telling your liver to slow down its glucose output. The combined effect brings blood sugar levels down without the risk of dangerously low blood sugar that some older diabetes medications carry. Semaglutide also slows the rate at which food leaves your stomach, which helps prevent blood sugar spikes after meals and contributes to feeling full longer.
Blood Sugar and Weight Effects
In clinical trials, Rybelsus at the 14 mg dose lowered HbA1c (a measure of average blood sugar over roughly three months) by about 1.5 percentage points over 52 weeks. For context, most diabetes guidelines consider a reduction of 0.5 percentage points or more clinically meaningful, so this is a substantial effect.
Weight loss is a consistent secondary benefit, though Rybelsus is not approved specifically as a weight loss drug. Over 26 weeks, patients taking the 7 mg dose lost an average of 5 pounds, while those on the 14 mg dose lost about 8 pounds. These numbers are modest compared to injectable semaglutide at higher doses, but for many people with type 2 diabetes, even this degree of weight loss improves insulin sensitivity and overall metabolic health.
Off-Label Use for Weight Loss
Some providers prescribe Rybelsus off-label for weight management in people without diabetes, though evidence in this population is still limited. A real-world study of 93 adults without diabetes found that one year on the 14 mg dose produced an average weight loss of about 5.7% of body weight (roughly 13 pounds). About 46% of participants achieved what researchers consider clinically significant weight loss, though most of those lost under 10% of their starting weight. The results varied widely from person to person.
Compared to injectable semaglutide at the higher doses approved for obesity, oral semaglutide at 14 mg produces less weight loss. It may be a reasonable option for people who strongly prefer a pill over an injection, or as a starting point before transitioning to more potent treatments.
How to Take It
Rybelsus has unusually specific instructions because the tablet needs an empty stomach and plain water to be absorbed properly. You take it first thing in the morning on an empty stomach with no more than 4 ounces of plain water. Then you wait at least 30 minutes before eating, drinking anything else, or taking other oral medications. Food, coffee, or other drinks during that window can significantly reduce how much of the drug your body absorbs.
The dosing follows a gradual schedule. You start at 3 mg daily for the first 30 days. This starting dose is purely to let your body adjust and does not provide meaningful blood sugar control on its own. After 30 days, the dose increases to 7 mg. If blood sugar control is still insufficient after at least another 30 days, your provider may increase to the maximum dose of 14 mg.
Common Side Effects
Gastrointestinal symptoms are the most frequent side effects, and they tend to be more common at higher doses. In placebo-controlled trials, 41% of patients on the 14 mg dose experienced some form of GI issue, compared to 32% on 7 mg and 21% on placebo. The specific breakdown for the 14 mg dose:
- Nausea: 20% (vs. 6% with placebo)
- Abdominal pain: 11%
- Diarrhea: 10%
- Decreased appetite: 9%
- Vomiting: 8%
- Constipation: 5%
These side effects are typically worst during the first few weeks at each new dose level, which is one reason the medication uses a gradual titration schedule. For most people, nausea and other GI symptoms fade as the body adjusts. Less common issues include acid reflux, bloating, and gas, each occurring in 2 to 3% of patients.
Who Should Not Take Rybelsus
Rybelsus carries a boxed warning, the FDA’s most serious safety label, related to thyroid tumors. In animal studies, semaglutide caused thyroid tumors including a type called medullary thyroid carcinoma. Whether this risk applies to humans is not fully established, but the medication is contraindicated for anyone with a personal or family history of medullary thyroid carcinoma or a condition called Multiple Endocrine Neoplasia syndrome type 2. If you have a history of either, this medication is not an option.